Communications Biology (Apr 2021)

A deimmunized and pharmacologically optimized Toll-like receptor 5 agonist for therapeutic applications

  • Vadim Mett,
  • Oleg V. Kurnasov,
  • Ivan A. Bespalov,
  • Ivan Molodtsov,
  • Craig M. Brackett,
  • Lyudmila G. Burdelya,
  • Andrei A. Purmal,
  • Anatoli S. Gleiberman,
  • Ilia A. Toshkov,
  • Catherine A. Burkhart,
  • Yakov N. Kogan,
  • Ekaterina L. Andrianova,
  • Andrei V. Gudkov,
  • Andrei L. Osterman

DOI
https://doi.org/10.1038/s42003-021-01978-6
Journal volume & issue
Vol. 4, no. 1
pp. 1 – 14

Abstract

Read online

Mett et al. describe development of GP532, a substantially deimmunized derivative of Toll-like receptor 5 (TLR5) agonist entolimod. GP532 has mutations eliminating key B- and T-cell epitopes and an inflammasome-activating domain yet remains a potent NF-κB activator with biological effects similar to entolimod. Thus, GP532 is suitable for multi-dose TLR5-targeting therapies and patients with high titers of preexisting flagellin-neutralizing antibodies.